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Objectives This study sought to determine the relationship between pre-transplant ventricular assist device (VAD) support
and mortality after heart transplantation.
Background Increasingly, VADs are being used to bridge patients to heart transplantation. The effect of these devices on
post-transplant mortality is unclear.
Methods Patients 18 years or older who underwent first-time, single-organ heart transplantation in the U.S. between
1995 and 2004 were included in the analyses. This study compared 1,433 patients bridged with intracorpo-
real and 448 patients bridged with extracorporeal VADs with 9,455 United Network for Organ Sharing sta-
tus 1 patients not bridged with a VAD with respect to post-transplant mortality. Because the proportional
hazards assumption was not met, hazard ratios (HRs) for different time periods were estimated.
Results Intracorporeal VADs were associated with an HR of 1.20 (95% confidence interval [CI]: 1.02 to 1.43;
p  0.03) for mortality in the first 6 months after transplant and an HR of 1.99 (95% CI: 1.44 to 2.75;
p  0.0001) beyond 5 years. Between 6 months and 5 years, the HRs were not significantly different from
1. Extracorporeal VADs were associated with an HR of 1.91 (95% CI: 1.53 to 2.37; p  0.0001) for mortal-
ity in the first 6 months and an HR of 2.93 (95% CI: 1.19 to 7.25; p  0.02) beyond 5 years. The HRs were
not significantly different from 1 between 6 months and 5 years, except for an HR of 0.23 (95% CI: 0.06 to
0.91; p  0.04) between 24 and 36 months.
Conclusions Extracorporeal VADs are associated with higher mortality within 6 months and again beyond 5 years after trans-
plantation. Intracorporeal VADs are associated with a small increase in mortality in the first 6 months and a clin-
ically significant increase in mortality beyond 5 years. These data do not provide evidence supporting VAD im-
plantation in stable United Network for Organ Sharing status I patients awaiting heart transplantation. (J Am
Coll Cardiol 2009;53:264–71) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.070s
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bentricular assist devices (VADs) are increasingly used to
uccessfully bridge patients to heart transplantation. Pa-
ients bridged with VADs typically show significant im-
rovement in end-organ function after implantation (1,2).
hese observations have contributed to the notion that
AD therapy may therefore render patients more medically
rom the *Department of Medicine, Division of Cardiovascular Medicine, University
f Massachusetts Medical School, Worcester, Massachusetts; and the †Division of
ardiology, Tufts Medical Center, Boston, Massachusetts. The data reported here
ave been supplied by the United Network for Organ Sharing as the contractor for the
rgan Procurement and Transplantation Network. The interpretation and reporting
f these data are the responsibility of the authors and in no way should be seen as an
fficial policy of or interpretation by the Organ Procurement and Transplantation
etwork or the U.S. Government.e
Manuscript received April 29, 2008; revised manuscript received July 14, 2008,
ccepted August 18, 2008.uitable to endure the rigors of cardiac transplantation.
espite the increase in use of VADs before transplantation,
tudies exploring the effect of VADs on post-transplant
ortality have yielded conflicting results. Although some
ingle-center studies analyzing outcomes from a limited
umber of patients have concluded that VAD therapy
efore heart transplantation is not related to post-transplant
See page 272
urvival, others have shown that VAD therapy is associated
ith improved post-transplant survival (3–9). Furthermore,
study has observed diminished survival for patients
ridged to transplant with a VAD (10).
We conducted a retrospective analysis in 11,336 patientsntered into the United Network for Organ Sharing
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January 20, 2009:264–71 VADs and Post-Transplant MortalityUNOS) Thoracic Registry to examine the relationship be-
ween intracorporeal and extracorporeal VAD implantation
nd post-transplant mortality.
ethods
his analysis was based on Organ Procurement and Trans-
lantation Network data as of May 25, 2006. We limited
ur analysis to patients in the UNOS Thoracic Registry who
ere 18 years or older and who underwent heart transplan-
ation between January 1995 and December 2004. The
nalysis was limited to first-time, single-organ heart trans-
lant recipients. Patients with a history of malignancy were
xcluded. Patients were divided into 3 groups based on the
upport at the time of transplant. The UNOS status 1 group
ncluded UNOS status 1 patients without VAD support at
he time of transplant. The intracorporeal VAD group
ncluded patients on a HeartMate (Thoractec Corporation,
aseline Characteristics
Table 1 Baseline Characteristics
Characteristic
UNOS Status I
(n  9,455)
Age (yrs)
Recipient 52
Donor 31.5
Difference 20.6
Recipient male 78.1
Sex mismatch 19.5
Time on wait list (days) 217
Ischemic cardiomyopathy 48.9
CMV mismatch (positive donor/negative recipient) 18.6
Ventilator 3.0
Inotropic support 83.2
Amiodarone 27.0
Diabetes 19.0
Serum creatinine 1.4
Total bilirubin 1.4
Cold ischemia time (h) 3.0
Most recent PRA (%) 3.5
VAD type
Novacor
Heartmate
Abiomed
Thoratec
Abiomed/Thoratec
Abiomed/Heartmate
Thoratec/Heartmate
Status at last follow-up
Alive 66.3
Dead 32.5
Repeat transplantation 1.1
Year of transplantation
1995–1996 21.6
1997–1998 22.4
1999–2000 20.5
2001–2002 18.5
2003–2004 17.0alues are mean or %. *From analysis of variance or chi-square test as appropriate.
CMV  cytomegalovirus; PRA  panel reactive antibodies; UNOS  United Network for Organ Sharing;leasanton, California) or Nova-
or (World Heart Inc., Oakland,
alifornia) intracorporeal VAD.
he extracorporeal VAD group
ncluded patients with a Thor-
tec (Thoractec Corporation) or
biomed (Abiomed Inc., Dan-
ers, Massachusetts) extracorpo-
eal VAD. Patients in either
AD group who were also on
n intra-aortic balloon pump
IABP) were excluded. Patients
ith both an intracorporeal and
n extracorporeal VAD were included in the extracorporeal
AD group. The primary outcome was all-cause mortality.
Baseline characteristics were compared among the 3
roups using analysis of variance, with the Tukey method
Intracorporeal VAD
(n  1,433)
Extracorporeal VAD
(n  448) p Value*
50.6 47.6 0.0001
31 32 0.20
19.6 15.5 0.0001
86.3 72.5 0.0001
16.6 14.1 0.0009
251 146 0.0001
51.0 46.0 0.14
19.9 14.3 0.03
2.1 12.5 0.0001
20.1 38.2 0.0001
31.5 31.0 0.0009
22.4 14.4 0.0004
1.3 1.4 0.0001
1.2 1.9 0.0003
3.2 3.4 0.0001
7.7 9.9 0.0001
10.2
89.8
24.6
73.6
0.2
0.4
1.1
72.0 66.3 0.0002
27.5 31.9
0.6 1.8
2.6 0.9 0.0001
6.1 1.3
25.4 13.2
36.8 44.6
29.1 40.0
Abbreviations
and Acronyms
HR  hazard ratio
IABP  intra-aortic balloon
pump
PRA  panel reactive
antibodies
UNOS  United Network for
Organ Sharing
VAD  ventricular assist
deviceVAD  ventricular assist device.
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VADs and Post-Transplant Mortality January 20, 2009:264–71or controlling for multiple comparisons, for continuous
ariables, and the chi-square test for categorical variables.
urvival curves were estimated using the Kaplan-Meier
ethod, and equality of survival curves was tested using a
og-rank test. The Cox proportional hazards regression
odel was used to estimate hazard ratios (HRs) of death in
he intracorporeal and extracorporeal VAD groups com-
ared with the UNOS status 1 group, after adjustment for
ovariates: donor and recipient age, recipient sex, sex mis-
atch (female donor–male recipient), time on waiting list,
schemic etiology of heart failure, cytomegalovirus-positive
onor/cytomegalovirus-negative recipient, recipient use of
entilator, inotropes and amiodarone before transplant,
ecipient history of diabetes, recipient’s serum creatinine
nd bilirubin, cold ischemia time, most recent panel reactive
ntibodies (PRA), and year of transplant. Proportional
azards assumption for each of the variables was examined
sing an interaction term with time. Ventilator use before
ransplant, serum bilirubin, PRA, and year of transplant
howed a significant interaction with time, and the interac-
ion term with time for these variables was retained in the
nal model. The relationship between intracorporeal or
xtracorporeal VAD use and mortality, using UNOS status
patients as the reference group, was found to be time
ependent. Therefore, HRs for different time periods were
stimated with the use of indicator variables that repre-
ented interaction between these groups and the different
Figure 1 Post-Transplant Survival of Patients on Intracorpore
Support Compared With UNOS Status 1 Patients W
Kaplan-Meier survival curves for survival after heart transplantation in each of the
based on the log-rank test of equality. UNOS  United Network for Organ Sharing;ime periods. Values of missing variables were replaced by
heir median value for continuous variables and their most
ommon value for categorical variables.
Secondary analysis was performed, treating various causes
f death as competing risks in the Cox proportional hazards
odel, in selected time periods in which the mortality
etween the groups was different, to identify the cause
esponsible for the difference in mortality (11). The causes
f death were grouped into 6 categories for this analysis:
ejection, infection, cardiovascular, pulmonary, malignant,
nd other (Online Appendix). A separate Cox proportional
azards model for each of these categories of death was
uilt, with adjustment for all of the variables as in the main
nalysis. In addition, malignancy in the donor was included
s a covariate in the model for death due to malignancy.
tatistical analysis was performed using SAS version 9.1
SAS Institute, Cary, North Carolina).
esults
atient population. There were 9,455 patients in the
NOS status 1 group, 1,433 patients in the intracorporeal
AD group, and 448 patients in the extracorporeal VAD
roup.
The median follow-up time was 49 months in the UNOS
tatus 1 group, 36.5 months in the intracorporeal VAD
roup and 24.4 months in the extracorporeal VAD group.
D
t VAD Support
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January 20, 2009:264–71 VADs and Post-Transplant Mortalityaseline characteristics. The baseline characteristics of
he 3 groups are summarized in Table 1. The etiology of
ardiomyopathy was similar between the groups. UNOS
tatus 1 patients were older than intracorporeal VAD
atients, who were older than the extracorporeal VAD
atients. Time on the waiting list was shorter for the
xtracorporeal VAD patients compared with UNOS status
and intracorporeal VAD patients. Creatinine was lower in
he intracorporeal VAD group than in the other 2 groups.
ilirubin was higher in the extracorporeal VAD group
ompared with the other 2 groups. The most recent PRA
as highest in the extracorporeal VAD group, followed by
he intracorporeal VAD group, followed by the UNOS
Figure 2 Post-Transplant Survival of Patients on Extracorpor
Support Compared With UNOS Status 1 Patients W
Kaplan-Meier survival curves for survival after heart transplantation in each of the
groups. The p value is based on the log-rank test of equality. Abbreviations as in F
urvival of Patients in the 3 Groups
Table 2 Survival of Patients in the 3 Groups
0 6 12 24
UNOS status 1
Survival (%) 100 89 86 81
Number left 9,455 8,313 7,849 6,886
Intracorporeal VAD
Survival (%) 100 87 85 80
Number left 1,433 1,239 1,155 955
Extracorporeal VAD
Survival (%) 100 78 75 70
Number left 448 345 312 237bbreviations as in Table 1.tatus 1 group. Extracorporeal VAD patients were more
ikely to be on a ventilator compared with the other 2
roups. Inotropic support was more common in the UNOS
tatus 1 group compared with the other 2 groups. Eight
ercent of patients in the UNOS status 1 group were
upported with an IABP. The majority of patients in the
xtracorporeal and intracorporeal VAD groups were trans-
lanted from 1999 to 2004, whereas patients in the UNOS
tatus 1 group were more evenly derived from 1995 to 2004.
he effect of VAD therapy on post-transplant mortality.
igures 1 and 2 and Table 2 summarize the unadjusted
urvival in each of the 3 groups after transplantation.
urvival curves in the intracorporeal VAD group and
AD
t VAD Support
1.
Time in Months
48 60 72 84 96 120
8 75 72 68 64 58 51
2 4,981 4,117 3,265 2,473 1,670 444
8 74 70 61 57 48 38
2 530 312 143 66 37 4
9 67 66 53 48 48 —
0 110 49 11 3 2 0eal V
ithou
2
igure36
7
5,91
7
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6
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VADs and Post-Transplant Mortality January 20, 2009:264–71NOS status 1 group were similar up to 48 months, when
hey started to diverge with decreased survival in the
ntracorporeal VAD group compared with the UNOS status
group. The overall p value for equality of survival between
he groups was 0.033 (Fig. 1). The rate of decline in survival
as steeper in the extracorporeal VAD group compared
ith the UNOS status 1 group in the first post-transplant
ear (Fig. 2). The decline in survival in the extracorporeal
AD group was equal to or less than that in the UNOS
tatus 1 group between 12 and 60 months. The smaller
umber of patients with follow-up 60 months in the
xtracorporeal VAD group makes survival estimates after
his time point in this group unreliable. The overall p value
or equality of survival between these groups was 0.0001.
Intracorporeal and extracorporeal VAD groups were as-
ociated with nonproportional time-dependent hazards for
ortality compared with the UNOS status 1 group. Thus,
Rs were obtained for different time periods and are shown
n Table 3. After adjusting for covariates mentioned in the
ethods section, the intracorporeal VAD group was asso-
iated with an HR of 1.20 (95% confidence interval [CI]:
.02 to 1.43) for mortality in the first 6 months after
ransplant compared with the UNOS status 1 group. Be-
ween 6 and 60 months, the HRs were not significantly
ifferent from 1, after which the HR for the intracorporeal
AD group was 1.99 (95% CI: 1.44 to 2.75) compared with
he UNOS status 1 group. The extracorporeal VAD group
ad an HR of 1.91 (95% CI: 1.53 to 2.37) for mortality
ompared with the UNOS status 1 group in the first 6
onths after transplant. Thereafter, HRs in this group
ecreased to 0.23 (95% CI: 0.06 to 0.91) at 24 to 36 months
nd remained diminished until 60 months, after which the
xtracorporeal VAD group was associated with an HR of
.9 (95% CI: 1.19 to 7.25) for mortality compared with the
NOS status 1 group.
auses of increased mortality. The results of the compet-
ng risks analysis to identify causes of increased mortality in
he VAD groups in selected time periods are shown in
ables 4 and 5. In the first 12 months post-transplant, the
ntracorporeal VAD group showed a trend toward increased
eath caused by infection. During this period, the extracor-
oreal VAD group experienced increased risk of death
aused by infections and due to other causes. Beyond 60
onths post-transplant, the intracorporeal VAD group
howed an increased risk of death caused by infection,
alignancy, and other causes. The number at risk was small
n the extracorporeal VAD group, yielding unreliable esti-
ates in this time period.
ffect of VADs on post-transplant mortality by era of
ransplantation. We examined the effect of VADs on
ost-transplant mortality by era of transplantation (1995 to
999 vs. 2000 to 2004) by introducing an interaction term of
he VAD group and the period of transplantation into the
odel. No significant difference was noted in the effect of
ntracorporeal or extracorporeal VADs on post-transplant
ortality between these time periods. iiscussion
he treatment options for patients with advanced heart
ailure or those with deteriorating end-organ function on
aximal medical management are limited to intravenous
notropes and mechanical assistance with IABP or VAD.
vidence from observational studies suggests that VADs are
uperior to IABP and inotropic support in successfully
ridging patients to transplantation (8,9). VADs have been
hown to improve cardiac output and end-organ function
1,2). A study by Deng et al. (12) compared mortality by the
rgency of placement of a VAD including semielective,
rgent, and emergent, and showed that the best outcomes
ere observed in patients who received VADs semielec-
ively. Gronda et al. (13) showed that patients receiving
azard Ratios for Post-Transplant Mortality
Table 3 Hazard Ratios for Post-Transplant Mortality
Variable
Hazard Ratio
(95% CI)* p Value
Intracorporeal VAD vs. UNOS status 1 (months)
0–6 1.20 (1.02–1.43) 0.03
6–12 0.80 (0.56–1.16) 0.24
12–24 1.06 (0.80–1.41) 0.7
24–36 0.84 (0.57–1.24) 0.38
36–48 1.18 (0.79–1.76) 0.42
48–60 1.22 (0.77–1.92) 0.4
60 1.99 (1.44–2.75) 0.0001
Extracorporeal VAD vs. UNOS status 1 (months)
0–6 1.91 (1.53–2.37) 0.0001
6–12 1.22 (0.72–2.06) 0.46
12–24 1.26 (0.79–2.01) 0.33
24–36 0.23 (0.06–0.91) 0.04
36–48 0.73 (0.27–1.97) 0.54
48–60 0.32 (0.05–2.30) 0.26
60 2.93 (1.19–7.25) 0.02
Recipient age 0.999 (0.996–1.002) 0.56
Donor age 1.01 (1.01–1.02) 0.0001
Recipient male 0.83 (0.77–0.91) 0.0001
Sex mismatch 1.08 (0.99–1.18) 0.07
Time on wait list (days) 1.00 (1.00–1.00) 0.11
Ischemic cardiomyopathy 1.08 (1.00–1.16) 0.04
CMV mismatch (positive donor/
negative recipient)
0.97 (0.88–1.05) 0.43
Ventilator 2.35 (1.96–2.82) 0.0001
Ventilator  time (months) 0.99 (0.98–0.99) 0.0001
Inotrope use 0.94 (0.86–1.03) 0.16
Amiodarone 1.03 (0.96–1.12) 0.42
Diabetes 1.22 (1.13–1.33) 0.0001
Serum creatinine (mg/dl) 1.04 (1.03–1.06) 0.0001
Total bilirubin (mg/dl) 1.03 (1.02–1.04) 0.0001
Bilirubin  time (months) 0.999 (0.999–1.00) 0.002
Cold ischemia time (h) 1.11 (1.07–1.15) 0.0001
Most recent PRA (%) 1.01 (1.00–1.01) 0.0001
Most recent PRA  time (months) 1.00 (1.00–1.00) 0.0007
Year of transplantation 0.95 (0.93–0.97) 0.0001
Year  time (months) 1.00 (1.00–1.002) 0.005
Adjusted for all variables in the table.
CI  confidence interval; other abbreviations as in Table 1.ntravenous inotropic support while awaiting transplanta-
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January 20, 2009:264–71 VADs and Post-Transplant Mortalityion for more than 21 days had a 50% mortality post-
ransplant. These observational data lend support to the
ypothesis that transitioning patients who are on inotropic
upport to VAD support may improve post-transplant
urvival. This idea, combined with the scarcity of donor
rgans, has led to an increasing number of transplant
ecipients being bridged to transplant with a VAD (14).
Several studies exploring effect of VADs on post-
ransplant outcomes have reported conflicting results, show-
ng improved, neutral, or even worse survival for patients
upported with VADs pre-transplant (3–10,14–19). One
tudy that used data from the Cardiac Transplant Research
atabase reported no significant difference in post-
ransplant survival between 502 patients treated with a left
entricular assist device (including 85 patients on an extra-
orporeal left ventricular assist device) and 2,514 patients on
ntravenous inotropes bridged to transplant between 1990
nd 1997 (20). In contrast, however, 4 of the last 6 annual
eports from the International Society for Heart and Lung
ransplantation registry reported increased early post-
ransplant mortality in patients supported with VADs
14–19). These data are in agreement with our own find-
ngs. Indeed, the primary strength of the current analysis is
hat it is a study with the largest number of patients to date
o help address this important issue in the care of patients
efore cardiac transplantation. We found that patients
ridged to transplant with intracorporeal VADs had a 20%
igher risk of mortality in the first 6 months after transplant
nd a nearly 2-fold higher risk of mortality beyond 5 years
isk of Cause-Specific Death Within the First 12 Months After Tran
Table 4 Risk of Cause-Specific Death Within the First 12 Mont
Cause of Death*
Number of Deaths
UNOS Status 1
(n  9,455)
Intracorporeal VAD
(n  1,433)
Rejection 173 21
Infection 276 49
Cardiovascular 246 33
Pulmonary 75 7
Malignancies 23 3
Other 568 104
See the Online Appendix for details of classification. †Compared with the UNOS status 1 group.
Abbreviations as in Table 3.
isk of Cause-Specific Death More Than 60 Months After Transpla
Table 5 Risk of Cause-Specific Death More Than 60 Months Af
Cause of Death*
Number of Deaths
UNOS Status 1
(n  4,111)
Intracorporeal VAD
(n  311)
Rejection 38 1
Infection 90 7
Cardiovascular 143 3
Pulmonary 30 2
Malignancies 87 10
Other 284 19See the online Appendix for details of classification. †Compared with the UNOS status 1 group. Adjuste
Abbreviations as in Table 3.ompared with UNOS status 1 patients. In absolute terms
his translates to 2% excess mortality at 6 months, 1% excess
ortality at 1 year, and 7% to 10% excess mortality at 6 to
years. The difference at 6 months and 1 year is small and
f unclear clinical significance, but the 7% to 10% excess
ortality at 6 to 8 years in the intracorporeal VAD group is
f considerable concern.
Patients bridged with extracorporeal VADs showed a
early 2-fold increase in mortality in the first 6 months after
ransplant compared with UNOS status 1 patients not
ridged with a VAD. These findings are consistent with the
esults from the registry of the International Society for
eart and Lung Transplantation (14,18,19,21). Beyond 6
onths, however, patients bridged with extracorporeal
ADs had a lower mortality compared with UNOS status
patients. This is probably the result of self-selection of
atients who were able to survive the initial post-transplant
eriod. Similar to the finding in patients with intracorporeal
ADs, patients bridged with extracorporeal VADs had a
igher mortality beyond 5 years of transplant compared
ith UNOS status 1 patients not bridged with a VAD,
lthough the number of patients for this analysis was small.
Infection seems to mediate part of the excess mortality in
he early post-transplant period in the extracorporeal and
ossibly in the intracorporeal VAD group. Although we did
ot have the data to look at, it is known that extracorporeal
AD patients are more likely to have biventricular failure
nd therefore a number of contributors to increased mor-
ality, including poor nutritional status and increased ino-
nt
ter Transplant
Hazard Ratio (95% CI)†
xtracorporeal VAD
(n  448) Intracorporeal VAD Extracorporeal VAD
10 0.91 (0.54–1.55) 1.34 (0.67–2.69)
23 1.41 (0.98–2.03) 2.17 (1.35–3.46)
19 0.89 (0.59–1.35) 1.55 (0.93–2.58)
5 0.60 (0.25–1.41) 1.48 (0.56–3.91)
1 1.17 (0.28–4.83) 2.36 (0.28–19.96)
54 1.07 (0.83–1.37) 1.66 (1.21–2.26)
d for variables listed in the Methods section.
ransplant
Hazard Ratio (95% CI)†
xtracorporeal VAD
(n  49) Intracorporeal VAD Extracorporeal VAD
1 0.42 (0.05–3.6) 6.47 (0.64–65.34)
0 3.26 (1.34–7.93) 0 (0–)
0 1.02 (0.3–3.41) 0 (0–)
0 1.47 (0.3–7.13) 0 (0–)
1 7.08 (3.24–15.48) 19.84 (2.19–179.6)
3 2.06 (1.23–3.47) 4.06 (1.19–13.91)spla
hs Af
Ent
ter T
Ed for variables listed in the Methods section.
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VADs and Post-Transplant Mortality January 20, 2009:264–71rope use, which could potentially explain the higher mor-
ality in this group compared with the intracorporeal VAD
roup in the immediate post-transplant period. The in-
rease in mortality in the intracorporeal VAD group attrib-
table to infection, malignancy, and other causes 5 years
eyond transplant is an intriguing finding. It has been
hown that patients with VADs have impaired cellular
mmunity (22,23). Although this can explain the trend
oward increased infections in patients bridged with VADs
n the early post-transplant period, the reason for increased
nfections in these patients 5 years after transplant is not
lear. Further study into this aspect of VADs is warranted.
he reason for increased death caused by malignancy in
ntracorporeal VAD patients is unclear. Ventricular assist
evices are associated with allosensitization (21). However,
e did not see increased mortality associated with rejection in
AD patients in our study. Allosensitization may play a role in
longer waiting time to transplant with intracorporeal VADs
21). It is not known whether this results in end-organ damage,
hich manifests as late increased mortality.
tudy limitations. Survival to transplant is an important
omponent of the overall effect of any intervention in
atients awaiting transplantation. We could not assess the
ffect of VADs on survival to transplant and could only
ssess their effect post-transplant. We therefore cannot
stimate the overall benefit or harm with VADs. Although
e adjusted for a variety of indicators of the patient’s illness
t the time of transplant, it is possible that there were
nmeasured differences between the groups that could
otentially bias the results. We did not have the indication
or VAD in the database and resorted to combining all
atients on VAD. It was therefore not possible to determine
he effect of VADs on post-transplant mortality by the
eason for VAD implantation (i.e., elective vs. clinical
nstability). Because the data used predate the appearance of
ontinuous flow devices, the results of this study cannot be
eneralized to these newer devices, which are gaining
opularity (24). Only a randomized controlled trial can
stablish the overall effect of VADs in stable status 1
atients awaiting transplantation.
onclusions
atients who are unstable or symptomatic despite maxi-
al medical therapy require VAD support as a bridge to
ransplant. One question raised by studies that have
hown improved end-organ function with VADs is
hether VADs improve post-transplant survival. Our
esults do not confirm this conclusion, but rather show
hat VADs are associated with increased early and late
ost-transplant mortality. Based on our results, we can-
ot recommend VAD implantation with a view to
mproving post-transplant survival for patients who are
table on intravenous inotropic therapy.eprint requests and correspondence: Dr. Rajan Krishnamani,
ivision of Cardiology, Tufts Medical Center, 800 Washington
treet, Box 5931, Boston, Massachusetts 02111. E-mail:
krishnamani@tuftsmedicalcenter.org.
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APPENDIX
or a classification of causes of death into
ategories, please see the online version of this article.
